Cough syrup linked to deaths of two children in Rajasthan; 22 batches of the drug banned - The Hindu
Authorities in Rajasthan have banned 22 batches of a cough syrup after the medicine was linked to the deaths of two children. The tragic incident raised serious concerns over the quality and safety of the drug. Following the fatalities, state health officials conducted immediate investigations and confirmed irregularities in certain batches of the syrup. The State Drug Controller has ordered an immediate recall to prevent further harm. Parents have been urged to stop using the affected product and return it to pharmacies. This incident underscores growing concerns about drug safety and quality control in India, where contaminated or substandard medicines have caused health crises in the past. Experts stress the urgent need for stricter enforcement of pharmaceutical manufacturing standards to protect patients, especially children, who are more vulnerable to toxic formulations. The government has also assured that further action will be taken against the manufacturer if negligence is proven.
The Key points
- Two child deaths in Rajasthan linked to cough syrup.
- Government bans 22 contaminated drug batches statewide.
- Health officials confirm quality issues in samples.
- Urgent recall of affected medicines ordered.
- Parents advised to discontinue and return the syrup.
- State Drug Controller leading detailed investigation.
- Manufacturer may face legal and regulatory action.
- Incident raises alarm over India’s drug safety monitoring.
- Experts demand stronger pharmaceutical quality checks.
- Children remain most vulnerable to unsafe formulations.
Disclaimer: This preview includes title, image, and description automatically sourced from the original website (www.thehindu.com) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
